Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Dementia Drugs Market, By Drug Class, By Indication, By Route of Administration, By Distribution Channel,By Geography
»óǰÄÚµå : 1672760
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 261¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR) 6.8%·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 414¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 261¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR 6.80% 2032³â ±Ý¾× ¿¹Ãø 414¾ï 5,000¸¸ ´Þ·¯
±×¸². Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Dementia Drugs Market-IMG1

Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÏ´Â °ÍÀº ¾ËÃ÷ÇÏÀÌ¸Ó º´ ¹× ±âŸ Ä¡¸Å ȯÀÚÀÇ ¼¼°è Áõ°¡ÀÔ´Ï´Ù. Ä¡¸Å´Â ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ³úÁ¹Áß°ú °°Àº ³ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúº´À¸·Î ÀÎÇÑ ÁõÈıºÀÔ´Ï´Ù. Ä¡¸Å´Â »ç°í, ±â¾ï, Ã߷аú °°Àº ÀÎÁö ±â´ÉÀÌ Á¡Â÷ÀûÀ¸·Î ¼Õ½ÇµÇ´Â °ÍÀ» Ư¡À¸·ÎÇÕ´Ï´Ù. Ä¡¸ÅÀÇ Áø´Ü°ú Ä¡·á¹ý¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, Ä¡¸ÅÀÇ Áõ»ó¿¡ ´ëÇØ ÀÇ·á±â°üÀÇ µµ¿òÀ» ¿ä±¸ÇÏ´Â »ç¶÷ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀϺΠÁ¦¾à ȸ»ç´Â Ä¡¸ÅÀÇ ÁøÇàÀ» ´ÊÃ߰ųª ¸ØÃß´Â È¿°úÀûÀÎ ¾à¹° ¿¬±¸ °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ½Å°æ ÅðÇ༺ ÁúȯÀÇ À§ÇèÀ» Áõ°¡½ÃŰ´Â ¼¼°è Àα¸ÀÇ ±Þ¼ÓÇÑ °í·ÉÈ­¸¦ À̲ø°í ÀÖ½À´Ï´Ù. ½ÅÈï±¹ ½ÃÀå¿¡¼­ÀÇ ÀÇ·á ÁöÃâ Áõ°¡¿Í ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷¿¡ ÀÇÇÑ ÁýÁßÀûÀÎ R&D ³ë·ÂÀÌ ½ÃÀå È®´ë¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ƯÈ÷ Èıâ ÀÓ»ó °Ë»ç¿¡¼­ ¸¹Àº Èĺ¸ ºÐÀÚ°¡ ½ÇÆÐÇϰí ÀÌ·¯ÇÑ Áúº´ÀÌ º¹ÀâÇϱ⠶§¹®¿¡ ³ôÀº ¾à¹° °³¹ß ºñ¿ëÀÌ Å« °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ´Ü¼øÈ÷ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó, Áúº´ÀÇ º´Àο¡ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÏ´Â Áúȯ °³ÁúÁ¦°¡ ÃÖ±Ù ½ÂÀÎµÈ °ÍÀº Á¦Á¶ÀÚ¿¡°Ô Å« ±âȸ°¡ µË´Ï´Ù. Ä¡¸Å ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø°ú ÀÚ±Ý Á¦°ø Áõ°¡´Â ½ÃÀå ÁøÃâ±â¾÷¿¡°Ô »õ·Î¿î Ä¡·á¹ýÀÇ Çõ½Å°ú °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àα¸µ¿ÅÂÀÇ º¯È­·Î ÀÎÇØ Ä¡¸ÅÀÇ À¯º´·üÀÌ °è¼Ó »ó½ÂÇÏ´Â °¡¿îµ¥ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ°í ½ÃÀåÀº Å« ÁøÀüÀ» ÀÌ·ê °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµÀ¸·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í º¹ÇÕ¿¬°£ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª¿¡ ÀÇÇÑ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.

Ä¡¸Å Ä¡·áÁ¦ ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀº ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î °Ô½ÃµË´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVe, Inc., DAICHI SAN ÇÕ´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

Ä¡¸Å Ä¡·áÁ¦ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚ´Â ¼¼°è Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦5Àå Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå, ÀûÀÀÁõº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦6Àå Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦7Àå Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦8Àå Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ºÐ¼®°¡ Ãßõ

Á¦11Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Dementia Drugs Market is estimated to be valued at USD 26.14 Bn in 2025 and is expected to reach USD 41.45 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 26.14 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.80% 2032 Value Projection: USD 41.45 Bn
Figure. Dementia Drugs Market Share (%), By Region 2025
Dementia Drugs Market - IMG1

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Dementia Drugs Market, By Drug Class, 2020-2032, (USD Bn)

5. Dementia Drugs Market, By Indication, 2020-2032, (USD Bn)

6. Dementia Drugs Market, By Route of Administration, 2020-2032, (USD Bn)

7. Dementia Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)

8. Dementia Drugs Market, By Region, 2020 - 2032, (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â